Hartmann´s Solution Fresenius Kabi

Hartmann’s Solution Fresenius Kabi is an intravenous electrolyte solution containing sodium lactate, potassium chloride, sodium chloride, and calcium chloride dihydrate. It is supplied as a sterile solution for injection, with the exact concentration not publicly disclosed, and is marketed in the European Union. The product is classified as a prescription‑only fluid and electrolyte replenishment used in clinical settings for volume expansion and electrolyte balance therapy.

Hartmann’s Solution Fresenius Kabi is indicated for clinical situations that require rapid restoration of extracellular fluid volume and electrolyte balance.

- Fluid resuscitation in hypovolemic shock - Electrolyte replacement in patients with deficits of sodium, potassium, calcium, or chloride - Peri‑operative fluid management to maintain hemodynamic stability - Burn and trauma care to compensate for fluid losses - Treatment of metabolic acidosis when lactate can be metabolized

Adverse reactions to Hartmann’s Solution Fresenius Kabi are generally related to the infusion of electrolytes and the volume administered.

Common: - Mild hypernatremia - Mild hyperkalemia - Mild hypocalcemia - Transient infusion site irritation - Mild metabolic alkalosis - Mild fluid overload

Serious: - Severe hypernatremia - Severe hyperkalemia - Severe hypocalcemia - Anaphylactic reaction - Pulmonary edema - Cardiac arrhythmia

When prescribing Hartmann’s Solution Fresenius Kabi, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risk.

- Assess baseline electrolyte levels and renal function before initiation - Adjust infusion rate in patients with heart failure or pulmonary edema - Use caution in patients with severe liver disease due to lactate metabolism - Avoid rapid large-volume infusions in neonates and infants - Monitor acid‑base status during prolonged therapy - Discontinue if signs of electrolyte imbalance develop

Hartmann’s Solution Fresenius Kabi may interact with other medications that affect electrolyte balance or fluid status.

Avoid: - Concurrent use of high‑dose potassium supplements or potassium‑sparing diuretics - Simultaneous administration of calcium gluconate infusions without monitoring - Co‑administration with hypertonic saline solutions

Use with caution: - Loop diuretics that may exacerbate electrolyte shifts - ACE inhibitors or ARBs in patients prone to hyperkalemia - Blood products that contain citrate, which can bind calcium